Video

Dr Stephen Silberstein on How Patients Are Reacting to CGRP Inhibitors

Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.

Stephen Silberstein, MD, director of the Jefferson Headache Center, discusses patient reactions to being prescribed a CGRP inhibitor.

Transcript:

How have patients reacted to being prescribed [calcitonin gene-related peptide] CGRP inhibitors?

In contrast to what we believed, patients are calling and rushing into the office to get the CGRP drugs because they're safe, they're effective, [they have] minimal if any side effects, and they don't have to take a pill every day.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Surbhi Sidana, MD, MBBS, Stanford University
Gordon Crofoot, MD, PA
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Hamlet Gasoyan, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo